Comparative Study of the Stability of Bimatoprost 0.03% and Latanoprost 0.005%: a Patient-use Study

Overview

Journal BMC Ophthalmol

Publisher Biomed Central

Specialty Ophthalmology

Date 2008 Jun 13

PMID 18547433

Citations 4

Authors

Mauricio D Paolera

Niro Kasahara

Cristiano C Umbelino

John G Walt

Affiliations

Soon will be listed here.

Abstract

Background: The stability of ophthalmic preparations in multidose containers is influenced by the preservative as well as the stability of the active ingredient. Unstable drugs may require refrigeration to preserve their active ingredient level and they are more likely to degrade over time, therefore becoming more susceptible to degradation based on patient mishandling. The purpose of this study was to determine the degree of molecular degradation that occurs in bimatoprost and latanoprost in a patient-use setting.

Methods: This was an open-label, laboratory evaluation of the relative stability of bimatoprost and latanoprost. Patients presently using bimatoprost (n = 31) or latanoprost (n = 34) were identified at 2 clinical sites in Brazil. Patients were instructed to use and store their drops as usual and return all used medication bottles between day 28 and day 34 after opening.

Results: Bimatoprost demonstrated no degradation, but latanoprost degraded at various levels. The mean age of bimatoprost was 43.0 +/- 3.4 days and the mean age of latanoprost was 43.9 +/- 2.8 days (P = .072). The mean percentage of labeled concentration was 103.7% in the bimatoprost bottles and 88.1% in the latanoprost bottles (P < 001).

Conclusion: This study showed that bimatoprost maintained > or =100% concentration throughout the study period while latanoprost did not.

Citing Articles

Evaluation of Physical Properties of Generic and Branded Travoprost Formulations.

Wadhwani M, Mishra S, Angmo D, Velpandian T, Sihota R, Kotnala A J Curr Glaucoma Pract. 2016; 10(2):49-55.

PMID: 27536047 PMC: 4981658. DOI: 10.5005/jp-journals-10008-1201.

Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations.

Angmo D, Wadhwani M, Velpandian T, Kotnal A, Sihota R, Dada T Int Ophthalmol. 2016; 37(2):423-428.

PMID: 27334605 DOI: 10.1007/s10792-016-0280-x.

Thermal stability of bimatoprost, latanoprost, and travoprost under simulated daily use.

Johnson T, Gupta P, Vudathala D, Blair I, Tanna A J Ocul Pharmacol Ther. 2010; 27(1):51-9.

PMID: 21117945 PMC: 3038126. DOI: 10.1089/jop.2010.0115.

Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.

Curran M Drugs Aging. 2009; 26(12):1049-71.

PMID: 19929032 DOI: 10.2165/11203210-000000000-00000.

References

Alm A, Widengard I, Kjellgren D, Soderstrom M, Fristrom B, Heijl A . Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995; 79(1):12-6. PMC: 505011. DOI: 10.1136/bjo.79.1.12. View

DuBiner H, Cooke D, Dirks M, Stewart W, VanDenburgh A, Felix C . Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001; 45 Suppl 4:S353-60. DOI: 10.1016/s0039-6257(01)00212-0. View

Varma R, Winarko J, Kiat-Winarko T, Winarko B . Concentration of latanoprost ophthalmic solution after 4 to 6 weeks' use in an eye clinic setting. Invest Ophthalmol Vis Sci. 2005; 47(1):222-5. DOI: 10.1167/iovs.04-1367. View

Laibovitz R, VanDenburgh A, Felix C, David R, Batoosingh A, Rosenthal A . Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol. 2001; 119(7):994-1000. DOI: 10.1001/archopht.119.7.994. View

Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K . Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000; 9(2):134-42. DOI: 10.1097/00061198-200004000-00002. View

Sherwood M, Brandt J . Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001; 45 Suppl 4:S361-8. DOI: 10.1016/s0039-6257(01)00219-3. View

Denis P, Lafuma A, Khoshnood B, Mimaud V, Berdeaux G . A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin. 2007; 23(3):601-8. DOI: 10.1185/030079907X178720. View

Walters T, DuBiner H, Carpenter S, Khan B, Vandenburgh A . 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol. 2004; 49 Suppl 1:S26-35. DOI: 10.1016/j.survophthal.2003.12.017. View

Alm A, Camras C, Watson P . Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 1997; 41 Suppl 2:S105-10. DOI: 10.1016/s0039-6257(97)80016-1. View

10.

Dirks M, Noecker R, Earl M, Roh S, Silverstein S, Williams R . A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv Ther. 2006; 23(3):385-94. DOI: 10.1007/BF02850159. View

11.

Diestelhorst M, Roters S, Krieglstein G . The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%. Graefes Arch Clin Exp Ophthalmol. 1997; 235(1):20-6. DOI: 10.1007/BF01007833. View

12.

Noecker R . Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2002; 18(5):205-15. DOI: 10.1007/BF02853166. View

13.

Fristrom B, Nilsson S . A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension. Br J Ophthalmol. 1998; 81(10):867-70. PMC: 1722025. DOI: 10.1136/bjo.81.10.867. View

14.

Gandolfi S, SIMMONS S, Sturm R, Chen K, VanDenburgh A . Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001; 18(3):110-21. DOI: 10.1007/BF02850299. View

15.

Sakai Y, Yasueda S, Ohtori A . Stability of latanoprost in an ophthalmic lipid emulsion using polyvinyl alcohol. Int J Pharm. 2005; 305(1-2):176-9. DOI: 10.1016/j.ijpharm.2005.08.017. View

16.

Noecker R, Dirks M, Choplin N, Bernstein P, Batoosingh A, Whitcup S . A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2002; 135(1):55-63. DOI: 10.1016/s0002-9394(02)01827-5. View

17.

Parrish R, Palmberg P, Sheu W . A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003; 135(5):688-703. DOI: 10.1016/s0002-9394(03)00098-9. View

18.

Morgan P, Proniuk S, Blanchard J, Noecker R . Effect of temperature and light on the stability of latanoprost and its clinical relevance. J Glaucoma. 2001; 10(5):401-5. DOI: 10.1097/00061198-200110000-00007. View

19.

Novack G, Evans R . Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization. J Glaucoma. 2001; 10(6):483-6. DOI: 10.1097/00061198-200112000-00008. View

20.

Fiscella R, Wilensky J, Chiang T, Walt J . Efficiency of instillation methods for prostaglandin medications. J Ocul Pharmacol Ther. 2007; 22(6):477-82. DOI: 10.1089/jop.2006.22.477. View